Home > Insider Trading > Filing (0001192482-19-000420)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1561921	Tela Bio Inc.	TELA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1339379	C Adele Oliva	C/O Quaker Bioventures Capital Ii, L.p. 150 Monument Road, Suite 207 Bala Cynwyd PA 19004		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-11-08	153,846	$13.00	888,664	No	4	P	Indirect	By Quaker Bioventures II, L.P.
Common Stock	Acquisiton	2019-11-13	345,489	$0.00	1,234,153	No	4	C	Indirect	By Quaker Bioventures II, L.P.
Common Stock	Acquisiton	2019-11-13	516,947	$0.00	1,751,100	No	4	C	Indirect	By Quaker Bioventures II, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Quaker Bioventures II, L.P.
No	4	C	Indirect	By Quaker Bioventures II, L.P.
No	4	C	Indirect	By Quaker Bioventures II, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-11-13	8,530,145	$0.00	345,489	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-11-13	12,763,434	$0.00	516,947	$0.00
Series B Preferred Stock	Warrant (right to buy)	Disposition	2019-11-13	446,813	$0.00	446,813	$1.16
Common Stock	Warrant (right to buy)	Acquisiton	2019-11-13	446,813	$0.00	18,096	$28.65

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect
0	2017-01-18	2027-01-18	No	4	C	Indirect
446,813	2019-11-13	2027-01-18	No	4	C	Indirect

Footnotes

Reflects 705,530 shares of common stock received as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise.
Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.